Review
General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase

https://doi.org/10.1016/0306-3623(94)90082-5Get rights and content

Abstract

1. The structure of catechol O-methyltransferase (COMT) has been recently characterized and a series of new and selective COMT inhibitors developed.

2. Entacapone, nitecapone and tolcapone are nitrocatechol-type potent COMT inhibitors in vitro (Ki in nanomolar range). They are also very selective for COMT and active in vivo even after oral administration. CGP 28014 is a pyridine derivative that is active only in vivo.

3. In animal studies, these compounds inhibit effectively the O-methylation of l-dopa, thus improving its bioavailability and brain penetration and potentiating its behavioural effects.

4. Entacapone and nitecapone have mainly a peripheral effect whereas tolcapone and CGP 28014 also inhibit O-methylation in the brain.

5. In man, entacapone, nitecapone and tolcapone all inhibit dose dependently the COMT activity in erythrocytes. These COMT inhibitors also decrease the amount of COMT dependent metabolites of adrenaline and noradrenaline in plasma.

6. In human volunteers, entacapone, tolcapone and CGP 28014 improve the bioavailability of l-dopa and inhibit the formation of 3-O-methyldopa.

7. In the first clinical studies in patients with Parkinson's disease, both entacapone and tolcapone potentiate and prolong the therapeutic effect of l-dopa.

References (89)

  • M. Salminen et al.

    Molecular cloning and characterization of rat liver catechol-O-methyltransferase

    Gene

    (1990)
  • E. Schultz et al.

    Inhibition of rat liver and duodenum soluble catechol-O-methyltransferase by a tight-binding inhibitor OR-462

    Biochem. Pharmac.

    (1989)
  • N.S. Sharpless et al.

    Effect of chronic administration of l-dopa on catechol-O-methyltransferase in rat tissues

    Life Sci.

    (1973)
  • C. Tilgmann et al.

    Purification and partial characterization of rat liver soluble catechol-O-methyltransferase

    FEBS Lett.

    (1990)
  • C. Tilgmann et al.

    Purification and partial sequence analysis of the soluble catechol-O-methyltransferase from human placenta: comparison to the rat liver enzyme

    Biochem. biophys. Res. Commun.

    (1991)
  • M. Törnwall et al.

    Effects of three types of catechol O-methylation inhibitors on L-3,4-dihydroxphenylalanine-induced circling behaviour in rats

    Eur. J. Pharmac.

    (1993)
  • M. Törnwall et al.

    Modulation of rat brain endogenous dopamine metabolism by new inhibitors of catechol O-methyltransferase

    Eur. J. Pharmac.

    (1993)
  • G. Tunnicliff et al.

    Kinetics of rat brain soluble catechol-O-methyltransferase and its inhibition by substrate analogues

    Int. J. Biochem.

    (1983)
  • R.W. Woodard et al.

    Stereochemical course of the transmethylation catalyzed by catechol O-methyltransferase

    J. biol. Chem.

    (1980)
  • E. Acquas et al.

    Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40-7592

    J. Neurochem.

    (1992)
  • K.H. Antonin et al.

    Effect of COMT inhibition by CGP 28 014 N-(6-hydroxy-2-pyridyl)-N′-di-N-propyl formamidine) on plasma dopa and 3OMD in humans

    Vth Clinical Pharmacology & Therapeutics

    (1992)
  • R. Bäckström et al.

    Synthesis of some novel potent and selective catechol-O-methyltransferase inhibitors

    J. med. Chem.

    (1989)
  • B. Bertocci et al.

    Human catechol-O-methyltransferase: cloning and expression of the membrane-associated form

  • P.R. Bieck et al.

    Effect of the new selective COMT inhibitor CGP 28014A on the formation of 3-O-methyldopa (3OMD) in plasma of healthy subjects

    J. neural. Transm.

    (1990)
  • P.R. Bieck et al.

    Clinical pharmacology of the new COMT inhibitor CGP 28 014

    Neurochem. Res.

    (1993)
  • J. Borgulya et al.

    Catechol-O-methyltransferase-inhibiting pyrocatechol derivatives: synthesis and structure-activity studies

    Helv. Chim. Acta

    (1989)
  • J. Borgulya et al.

    Ro 40-7592

    Catechol-O-methyltransferase (COMT) inhibitor

    Drugs Future

    (1991)
  • J.M. Cedarbaum et al.

    Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys: implications for the treatment of Parkinson's disease

    Clin. Neuropharmac.

    (1991)
  • P. Cumming et al.

    Formation and clearance of interstitial metabolites of dopamine and serotonin in the rat striatum: an in vivo microdialysis study

    J. Neurochem.

    (1992)
  • M. Da Prada et al.

    New therapeutic strategies in Parkinson's disease: inhibition of MAO-B by Ro 19-6327 and COMT by Ro 40-7592

  • T.L. Davis et al.

    Tolcapone (Ro 40-7592) in combination with Sinemet and selegiline in Parkinson's disease

    Ann. Neurol.

    (1993)
  • E. Etemadzadeh et al.

    Computerized rotometer apparatus for recording circling behavior

    Meth. find. exp. clin. Pharmac.

    (1989)
  • G. Firnau et al.

    Cerebral metabolism of 6-[18F]fluoro-l-3,4-dihydroxyphenylalanine in the primate

    J. Neurochem.

    (1987)
  • G. Firnau et al.

    Metabolites of 6-[18F]fluoro-l-dopa in human blood

    J. nucl. Med.

    (1988)
  • H.C. Guldberg et al.

    Catechol-O-methyl transferase: pharmacological aspects and physiological role

    Pharmac. Rev.

    (1975)
  • M. Guttman et al.

    Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa

    Mov. Disord.

    (1993)
  • P. Hartvig et al.

    Regional brain kinetics of 6-fluoro-(β-11C)-l-dopa and (β-11C)-l-dopa following COMT inhibition

    A study in vivo using positron emission tomography

    J. neural Transm. gen. Sect.

    (1992)
  • D.R. Jeffery et al.

    Kinetic reaction mechanism for magnesium binding to membrane-bound and soluble catechol O-methyltransferase

    Biochemistry

    (1987)
  • P. Jenner et al.

    Interaction of the COMT inhibitor entacapone with l-dopa in MPTP treated common marmosets

    Can. J. neurol. Sci.

    (1993)
  • S. Kaakkola et al.

    Effects of catechol-O-methyl-transferase inhibitors and l-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular-dopamine in rat striatum

    J. Neurochem.

    (1993)
  • S. Kaakkola et al.

    Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients

    Neurology

    (1994)
  • S. Kaakkola et al.

    Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of l-dopa in healthy volunteers

    Clin. Neuropharmac.

    (1990)
  • T. Keränen et al.

    Effect of the novel catechol-O-methyltransferase inhibitor, OR-611, on the pharmacokinetics and metabolism of levodopa

  • T. Keränen et al.

    The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers

    Clin. Neuropharmac.

    (1993)
  • Cited by (126)

    • Parkinson's disease

      2020, Drug Delivery Devices and Therapeutic Systems
    • Pharmacodynamic evaluation of novel Catechol-O-methyltransferase inhibitors

      2019, European Journal of Pharmacology
      Citation Excerpt :

      S-COMT has a higher enzymatic capacity than MB-COMT (Vmax up to nearly 15,000 pmol/min per mg protein in liver) (Guldberg and Marsden, 1975; Roth, 1992). S-COMT has therefore a more predominant role when substrate levels are high and is believed to be primarily involved in the O-methylation and elimination of biologically active, toxic and mainly exogenous catechols (such as food-derived catechol compounds in the gut), acting as an enzymatic detoxifying barrier between the blood and other tissues (Kaakkola et al., 1994; Mannisto and Kaakkola, 1999; Mannisto et al., 1992). On the other hand, MB-COMT has a low enzymatic capacity (Vmax of only 2–40 pmol/min per mg protein), a higher affinity for catechol substrates, and a lower Km value (Km = 10 μM) for dopamine than S-COMT (Km = 108 μM), and as such is thought to be predominant at low substrate levels (Malherbe et al., 1992).

    • Methyltransferases

      2018, Comprehensive Toxicology: Third Edition
    View all citing articles on Scopus
    View full text